Document is current
Any future updates will be listed below
-
Authors
Kubeš, Jan https://orcid.org/0000-0002-0513-4847
Karabanovich, Galina
Cong, Anh T. Q. https://orcid.org/0000-0001-9307-7741
Melnikova, Iuliia
Lenčová, Olga
Kollárová, Petra https://orcid.org/0000-0001-9673-9210
Bavlovič Piskáčková, Hana https://orcid.org/0000-0002-9817-7247
Keresteš, Veronika
Applová, Lenka
Arrouye, Lise C. M.
Alvey, Julia R. https://orcid.org/0000-0001-6549-9816
Paluncic, Jasmina https://orcid.org/0000-0003-3420-1532
Witter, Taylor L. https://orcid.org/0000-0003-3096-3011
Jirkovská, Anna
Kuneš, Jiří
Štěrbová-Kovaříková, Petra
Austin, Caroline A. https://orcid.org/0000-0002-1921-5947
Štěrba, Martin
Šimůnek, Tomáš
Roh, Jaroslav
Schellenberg, Matthew J. https://orcid.org/0000-0001-7036-5943
-
Funding
Funding for this research was provided by:
Mayo Clinic (startup funds)
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 14 May 2025
First Online: 28 May 2025
Competing interests
: Obex compounds have been patented by Charles University and Mayo Clinic, with M.J.S., J.R., T.S., J.Kub, G.K., I.M., O.L., P.K., V.K., and M.S. listed as inventors (US patent application No. 63/534,074, 2023 and PCT application number PCT/US2024/043047). The remaining authors declare no competing interests.
